Drugs / BM-Allo.MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04397796 | Aug → Sep 2020 | COVID-19 | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM-Allo.MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04397796 ↗ |
| Modality | Cell therapy | “Immunomodulatory Mesenchymal Stem Cells” NCT04397796 ↗ |
| Route | Other | “BM-Allo.MSC for Infusion” NCT04397796 ↗ |